B of A Securities Maintains Neutral on Moderna, Lowers Price Target to $150
Portfolio Pulse from jenniferd'souza@benzinga.com
B of A Securities analyst Geoff Meacham maintains a Neutral rating on Moderna (NASDAQ:MRNA) and lowers the price target from $175 to $150.
August 04, 2023 | 4:54 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
B of A Securities has maintained a Neutral rating on Moderna and lowered the price target from $175 to $150.
The lowering of the price target by B of A Securities indicates a potential decrease in the stock's value. This could lead to a short-term negative impact on Moderna's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100